Ireland
--:--IST
Latest
Clinical Trials in Canada / NCT06828484
Active, not recruiting Not applicable

Allergenic Extract Standardized Cat Hair AP in an Allergic Rhinitis Model.

NCT06828484 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2025-03-04
Last updated
2026-01-20

Condition(s) studied

Allergic Rhinitis

Investigational drug(s) / intervention(s)

Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP)

Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP): Cat-allergic and non-allergic participants will be exposed to AP Cat in the NAC.

Study summary

The goal of this study is to learn if a cat allergen extract known as Allergenic Extract Standardized Cat Hair Acetone Precipitated (AP Cat) can induce allergic rhinitis (AR) in a nasal allergen challenge model in cat-allergic people. The main questions this study aims to answer are:

1. Does AP Cat induce nasal symptoms of allergic rhinitis in cat-allergic participants when delivered intranasally?
2. Does AP Cat reduce elements in the blood and nose that are known to be associated with allergies?

Both allergic and non-allergic participants will be recruited into this study.

Allergic participants will:

* Be challenged with AP Cat via the Nasal Allergen Challenge (NAC), which involves administration of this allergen extract directly into the nose.
* Have nasal fluid and blood samples collected at various timepoints up to 24 hours after exposure to the allergen in the NAC.
* Visit the study site three separate times:

1. At screening (Visit 1), to determine eligibility to participate in this study
2. At the baseline NAC visit (Visit 2)
3. At the 24-hour post-NAC follow-up visit (Visit 3)
* Complete nasal symptom questionnaires.
* Complete a questionnaire about their regular exposure to cats.

Non-allergic participants will:

* Be challenged with AP Cat via the NAC, which involves administration of this allergen extract directly into the nose.
* Have nasal fluid and blood samples collected at various timepoints up to 24 hours after exposure to the allergen in the NAC.
* Visit the study site three separate times:

1. At screening (Visit 1), to determine eligibility to participate in this study
2. At the baseline NAC visit (Visit 2)
3. At the 24-hour post-NAC follow-up visit (Visit 3)
* Complete nasal symptom questionnaires.

This study will compare the nasal symptoms and allergic markers collected from the nasal fluid and blood samples between allergic and non-allergic participants at baseline and various timepoints post-NAC exposure.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria: To be considered for inclusion in this study, all participants must be: * A healthy, ambulatory male, female, or intersex volunteer between the ages of 18 to 70 years of age. * Able to understand and willing to provide written informed consent. * Able and willing to comply with study requirements. To be enrolled as an allergic participant, participants must: * Have a minimum 2-year history of AR symptoms upon exposure to cats. * Have a positive skin prick response to AP cat allergen, defined as a wheal diameter ≥ 5 mm compared to the negative control wheal. This result must be achieved at visit 1. * Have a TNSS of greater than or equal to 8/12 and at least a 50% drop in PNIF in response to the allergen titration challenge at visit 1. To be enrolled as a non-allergic participant, participants must: * Produce a negative skin test response to a panel of relevant aeroallergens tested at visit 1 or within 12 months before visit 1 at the research site. * Produce a negative Nasal Allergen Challenge, defined by a TNSS response of less than 4/12 and a PNIF reduction of less than or equal to 20% after 10 minutes in response to the highest allergen concentration at visit 1. Exclusion Criteria: * Participant has abnormalities detected on physical examination considered by the investigator to be clinically significant. * Participant has a history of any disease or disorder that, in the judgement of the investigator, would impact the participant's safety or the results of the study. * Participant has a significant history of alcohol or drug abuse in the judgment of the Principal Investigator or delegate. * Participant is pregnant, lactating, or actively trying to become pregnant. * Participant is unable to comply with the washout periods for restricted medications. * Participant has signs/symptoms of active seasonal AR or is allergic to a seasonal allergen that is present in the outdoor environment during visit 1 and visit 2 and which the Principal Investigator judges would impact the outcome of the study. * Participant has any structural nasal abnormalities or nasal polyps on examination or a history of frequent nose bleeding, as determined by a nasal examination at screening and prior to the NAC, in the judgement of the principal investigator. * Participant has undergone nasal surgery within the previous 3 months before visit 1. * Participant has experienced an upper or lower respiratory infection within 2 weeks prior to the NAC visit. * Participant exhibits any signs or symptoms of a respiratory infection prior to any visit, as per Principal Investigator judgement. * Participant reports a TNSS of greater than or equal to 4 prior to the titration challenge at visit 1 or immediately prior to allergen challenge at visit 2, as per Principal Investigator judgement. * Participant reports a TNSS change of greater than 2 from baseline, after the diluent challenge at visit 1. * Participants with asthma requiring the use of a short-acting beta agonist greater than twice a week (unless for viral asthma) or with severe asthma requiring maintenance high doses of inhaled or oral corticosteroids or biologic therapy (Omalizumab/Mepolizumab/Resilizumab). * Participant has a history of cat allergen induced asthma, unless well controlled on low-dose inhaled corticosteroids or PRN inhaled corticosteroid/long-acting beta-agonist as per Principal Investigator discretion. * Participant is currently receiving cat allergen specific immunotherapy or concluded a course of cat immunotherapy in the last 3 years. * Participant has a history of positive test results for HIV, Tuberculosis (not due to vaccination), Hepatitis B (not due to vaccination) or Hepatitis C. * Participant has received an investigational product within the previous 30 days. * Participant is unable and/or unlikely to comprehend and/or follow the protocol over the duration of the study. Participant is unwilling to attend study visits or adhere to the study protocol, in the judgement of the Principal investigator.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Kingston Health Sciences Centre - Kingston General Hospital Kingston Ontario

More Queen's University trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06828484 on ClinicalTrials.gov ↗ ← All trials in Canada